BOT is going to move fast to get this to market. The results coming this quarter and next quarter could give it multiples of this market cap due to the high likelihood of a partnership or TO. A partnership agreement could be made not long after the results this quarter to fully fund the rest of the trials and take it through to commercialization. I genuinely think BOT has a position of power due to no significant or only minor breakthroughs in the past 20 years and essentially a more 'natural' alternative than what's available for the targeted skin diseases. Also the Permetrex technology is worth a large MC in itself. The drugs available on the market now have significant side effects and the chemicals they use to penetrate the skin to deliver the treatment drys the skin, not ideal when treating skin disease. If the product is sold for $2000-$5000USD, that will be a huge profit margin. How the next 6 months plays out is going to be so interesting.
BOT Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)